Prostate cancer is the most frequent nonskin cancer and second most common cause of
cancer-related deaths in man. Prostate cancer is a clinically heterogeneous disease with …

Background Between 1999 and 2009 in the United Kingdom, 82,429 men between 50 and
69 years of age received a prostate-specific antigen (PSA) test. Localized prostate cancer …

Urinary incontinence is a common and predictable consequence among men with localized
prostate cancer who have undergone radical prostatectomy. Despite advances in the …

Background The use of 12-core systematic prostate biopsy is associated with diagnostic
inaccuracy that contributes to both overdiagnosis and underdiagnosis of prostate cancer …

Subclinical prostate cancer is common in men> 50 years. Population-based screening of
men aged between 55 and 69 years, using prostate-specific antigen (PSA) testing, has been …

Background Very long-term mortality in men with early prostate cancer treated with surgery
versus observation is uncertain. Objective To determine long-term effects of surgery versus …

Background Plant-based diets are associated with multiple health benefits and a favorable
environmental impact. For prostate cancer, previous studies suggest a beneficial role of …

Prostate cancer (PCa) is one of the first three causes of cancer mortality in Europe.
Screening in asymptomatic men (aged 55–69 yr) using prostate-specific antigen (PSA) is …

Importance The Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP)
reported no effect of prostate-specific antigen (PSA) screening on prostate cancer mortality …

Background All risk stratification strategies in cancer overlook a spectrum of disease. The
Prostate MR Imaging Study (PROMIS) provides a unique opportunity to explore cancers that …